Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Farnaz Tabatabaian"'
Publikováno v:
Annals of allergy, asthmaimmunology : official publication of the American College of Allergy, Asthma,Immunology.
Autor:
Michell Lozano-Chinga, Natalie Diaz-Cabrera, Farhad Khimani, Karin Chen, John Bohnsack, Jolan E. Walter, Farnaz Tabatabaian, Zeinab Afify
Publikováno v:
Journal of pediatric hematology/oncology. 44(3)
Primary immunodeficiency diseases are associated with an increased tendency for noninfectious complications of autoimmunity and malignancy, particularly leukemia and lymphoma. The mechanisms of immune dysregulation have been linked to the combination
Autor:
Tara V. Saco, Farnaz Tabatabaian
Publikováno v:
Allergens and Allergen Immunotherapy ISBN: 9781351208994
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62f5a0ae5bbb7ba24e1d756857f8dddc
https://doi.org/10.1201/9781351208994-32
https://doi.org/10.1201/9781351208994-32
Autor:
Farnaz Tabatabaian, Thomas B. Casale
Publikováno v:
Expert Review of Clinical Immunology. 14:191-196
Allergic rhinitis (AR) is characterized by the presence of congestion, postnasal drainage, sneezing and rhinorrhea. AR contributes to reduced productivity and significant morbidity worldwide. Areas covered: We review data emphasizing that the most ef
Publikováno v:
Drugs. 76:999-1013
Asthma is a complex disease where many patients remain symptomatic despite guideline-directed therapy. This suggests an unmet need for alternative treatment approaches. Understanding the physiological role of muscarinic receptors and the parasympathe
Autor:
Dennis K. Ledford, Farnaz Tabatabaian
Publikováno v:
Journal of Asthma and Allergy
Asthma is a heterogeneous syndrome with numerous underlining molecular and inflammatory mechanisms contributing to the wide spectrum of clinical phenotypes. Multiple therapies targeting severe asthma with type 2 (T2) high inflammation are or soon wil
Autor:
Farnaz Tabatabaian
Publikováno v:
Allergy and Asthma ISBN: 9783319587264
Allergy and Asthma
Allergy and Asthma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a8a967c80a5cd71bdf7981d73d030dc
https://doi.org/10.1007/978-3-319-58726-4_12-1
https://doi.org/10.1007/978-3-319-58726-4_12-1
Autor:
Farnaz Tabatabaian, Thomas B. Casale
Publikováno v:
Allergy and Asthma Proceedings. 36:100-104
Allergy immunotherapy has been used to help alleviate symptoms of allergic diseases for over 100 years. In the setting of the recently approved sublingual immunotherapy, allergists are now faced with which therapeutic regimen to use in clinical pract
Publikováno v:
Immunology and allergy clinics of North America. 37(2)
Several biologics are currently FDA approved for asthma that target Th2 high patients. Unfortunately, 50% of patients with severe asthma do not fit this phenotype of disease and have fewer effective therapeutic options. In the clinical setting, total
Publikováno v:
Journal of Biological Chemistry. 285:18991-19001
The mammalian target of rapamycin (mTOR) and S6 kinase (S6K) pathway is essential for cell differentiation, growth, and survival. Phospholipase D2 (PLD2) plays a key role in mTOR/S6K mitogenic signaling. However, the impact of PLD on mTOR/S6K gene ex